

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 04843/112002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/556,134
		Applicant Yurgelun-Todd et al.
		Filing Date February 12, 2007
		Group 1651
		IDS Filed November 24, 2010
(37 C.F.R. § 1.98(b))		

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	6,498,143	Dec. 24, 2002	Beck et al.
	6,790,825	Sep. 14, 2004	Beck et al.

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Anonymous. "Repligen Discovers Site of Brain Activation by Secretin in Animal Studies Repligen and McLean Hospital to Extend Discovery Through Clinical Trial." <i>Repligen Corporation: Press Release</i> , November 12, 2001. (2 pages)
	Anonymous. "Secretin is Active in a Brain Region Implicated in Autism." <i>McLean This Week</i> , November 4, 2002. (1 page)
	Chez et al. "Secretin and Autism: A Two-Part Clinical Investigation." <i>J. Autism Dev. Disord.</i> 30:87-94. (2000)
	Dunn-Geier et al. "Effect of Secretin on Children with Autism: A Randomized Controlled Trial." <i>Dev. Med. Child Neurol.</i> 42:798-802. (2000)
	Repligen Corporation. "SecreFlo™ (Secretin) for Injection." (2002) (2 pages)
	Rioux et al. "Secretin iv Induces Gene Activation and fMRI Changes in the Amygdala: Potential Relationship to Behavioral Improvements Seen in Treating Autistic Children." American College of Neuropsychopharmacology, Annual Meeting (2002) (abstract, 1 page)
	Robinson. "Homeopathic Secretin in Autism: A Clinical Pilot Study." <i>Br. Homeopath. J.</i> 90:86-91. (2001)
	Strakowski et al. "Brain Magnetic Resonance Imaging of Structural Abnormalities in Bipolar Disorder." <i>Arch. Gen. Psychiatry</i> , 56:254-60. (1999)
	Yurgelun-Todd et al. "Increased Amygdala fMRI Activation After Secretin Administration." Society of Biological Psychiatry, 58th Annual Convention and Scientific Program. (2003) (abstract, 1 page)
	Yurgelun-Todd et al. "Increased Amygdala fMRI Activation After Secretin Administration." <i>Exp. Clin Psychopharmacol.</i> 16:191-198. (2008)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	